MARINUS PHARMACEUTICALS, INC. The Epilepsy Pipeline landscape is evolving with increased insight into biological pathways and mechanisms underlying Epilepsy, leading towards more targeted therapies.
DelveInsight's Epilepsy Pipeline Insight 2021 report offers exhaustive global coverage of available, marketed, and pipeline therapies under different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Epilepsy pipeline domain.
Some of the essential takeaways from the Epilepsy Pipeline report:*DelveInsight's Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies. *Major pharmaceutical companies are developing potential drug candidates to improve the Epilepsy treatment scenario, such as
Request for Epilepsy sample report to learn more about trends in specific geographies @ Epilepsy Emerging Therapies and Forecast
The Epilepsy pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Epilepsy products, comprehensive assessment of driving and restraining factors, and opportunities as well as risks in the Epilepsy pipeline landscape.
Epilepsy Overview
Epilepsy is a chronic neurological disorder characterized by frequent and recurring seizures leading to unusual behavior. The primary cause of Epilepsy is not clear, but it is noted that any change in the nerve cells, neurons, and the brain resulting in abnormal signals can be the possible reason.
The most common symptom of Epilepsy includes seizures; however, additional symptoms like convulsion without fever, low consciousness, less awareness, loss of taste, smell, sight, hearing, etc., can also be present.
For further information about Epilepsy treatment and pipeline therapies, visit @ Epilepsy Pipeline Assessment
Epilepsy Pipeline Drugs
Drug
Company
Phase
MoA
RoA
OPC-214870
Phase I
Antiepileptic
Oral
CT-010
Phase II
4-aminobutyrate transaminase inhibitors
Intraventricular
Ganaxolone
Phase III
GABA A receptor agonists
Intravenous
XEN496
Phase III
KCNQ potassium channel agonists
Oral
Vatiquinone
Phase II/III
NQO1 modulators
Oral
E-2730
Phase II
Synaptic transmission modulators
Oral
NBI 827104
Phase II
T type calcium channel antagonists
Oral
Epilepsy Therapeutics Assessment
The Epilepsy Pipeline report proffers an integral view of the Epilepsy emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type*Mono *Combination *Mono/Combination
By Stage*Discovery *Pre-clinical *Phase I *Phase II *Phase III *Pre-registration
By Route of Administration*Subcutaneous *Intravenous *Oral *Intraventricular *Inhalation
By Molecule Type*Gene therapy *Stem cell therapy *Small molecules *Pyridines
By Mechanism of Action*4-aminobutyrate transaminase inhibitors *GABA A receptor agonists *KCNQ potassium channel agonists *NQO1 modulators *Serotonin receptor agonists *T type calcium channel antagonists
By Targets*GABA A receptor *KCNQ potassium channel *Serotonin receptor *NQO1 *T type calcium channel *Synaptic transmission
Dive deep into rich insights of Epilepsy novel and emerging drugs and their analysis @ Epilepsy Pipeline Emerging Novel Therapies
Scope of the Epilepsy Pipeline Report*Coverage: Global *Major Players:
Table of Contents
1
Introduction
2
Executive Summary
3
Epilepsy: Overview
4
Epilepsy - Analytical Perspective In-depth Commercial Assessment
5
Pipeline Therapeutics
6
Late Stage Products (Phase III)
7
Late Stage Products (Phase II/III)
8
Mid Stage Products (Phase II)
9
Early Stage Products (Phase I)
10
Therapeutic Assessment
11
Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Epilepsy Key Companies
14
Epilepsy Key Products
15
Epilepsy- Unmet Needs
16
Epilepsy- Market Drivers and Barriers
17
Epilepsy- Future Perspectives and Conclusion
18
Epilepsy Analyst Views
19
Appendix
20
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit https://www.delveinisght.com/blog/
Media Contact
Company
Contact Person:
Email: info@delveinsight.com
Phone: +19193216187
Address:
City: Albany
State:
Country:
Website: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
Source: www.abnewswire.com
.
(C) 2022 M2 COMMUNICATIONS, source
